Radioimmunoassay systems have been developed to quantitate virtually every hormone and enzyme in the body. Utilizing the potent tools of radioactivity and immunology, these exquisitely sensitive techniques have revolutionized the fields of endocrine physiology and clinical endocrinology. RIA, as the name implies, achieves sensitivity through the use of radionudi4es and specificity that is uniquely associated with immunochemical reactions 1 . Development of radioimmunoassay initiated with the publication by Greenwood and Hunter 2-4 , demonstrating I-13 1 labelling of proteins using Chloramine-T while fully retaining immunological activity. Yalow and Berson published their RIA for insulin [5] [6] [7] [8] and Roger Ekins came up with determination of serum thyroxine using a competitive binding assay 9, 10 . The radioimmunological determination of thyroid stimulating hormone was first published by Odell 11 and for thyroid hormones by Murphy et al 12 . The discovery that happens coupled to carrier proteins could also invoke an antibody production accelerated the development of radioimmunoassays for steroids and low molecular weight substances [13] [14] [15] [16] [17] [18] [19] [20] . The importance of this method lies in permitting the quantitative measurement of extremely small fractions, in the order of nanogram (10 g) and picogram (10 g), while the measurement is highly specific due to the immunological character of the reaction. The application of this technique to the measurement of protein and peptide hormones was an important advancement in the biochemistry of hormones and endocrinology. Before the advent of radioimmunoassays, the assay of polypeptide hormones was mostly considered a research topic, and their assessment was made indirectly. The earlier method of measuring peptide hormone in plasma was based on bioassay. This was performed by comparing the hormonal effect produced by an unknown in a laboratory animal with that produced by a known standardized preparation of the hormone. Several bioassays have been developed. However, they generally lacked sensitivity or specificity. To improve both sensitivity and specificity, it became necessary to concentrate the hormone in question from a large volume of animal plasma. This animal preparation, as well as the processing of the material for use, was time consuming and tedious. Although these methods yielded much physiological information, the technical requirements and poor reproducibility restricted the clinical use of bioassays to relatively few laboratories 21 . The direct chemical assay of peptide hormones was likewise fraught with problems. The chemical assay of thyroidal and steroidal hormones is possible because they possess distinctive chemical groupings. In addition, their concentration in plasma are three to five orders of magnitude higher than those of the peptide hormones. Unlike thyroidal and steroidal hormones, peptide hormones have evaded accurate assay because they are very few uniquely reacting groups that can be used to identify the hormone in the presence of other peptides. Even when specific reaction sites do exist on the hormone in question, they are not readily distinguishable from the remainder of the plasma proteins, which are present at a million-fold to billion-fold higher concentration. Radioimmunoassay methods possess the unique advantage of being sensitive, specific, and precise and therefore have gained the widest acceptance. The pace of new developments in RIA makes it impossible to create a "current" list of RIA applications 20 . The applications in cardiology, rheumatology, gastroenterology and gynaecology soon followed rapidly 22 . Drugs that are used in generally low concentration are difficult to measure chemically and are increasingly being measured by RIA. Most drugs are relatively small molecules with molecular weights less than 1000, are nonimmunogenic. Landsteiner 23 showed that many small molecules (called haptens) could be covalenTtly linked to larger carrier molecules such as proteins, poly-peptides and poly-saccharides. Antibodies
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